Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer discontinues lung cancer drug trials
This includes two phase 3 clinical trials and two phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical in 2005. An analysis of the trials by
This includes two phase 3 clinical trials and two phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical in 2005. An analysis of the trials by
The US approval of Exforge was supported by a clinical program involving more than 5,000 patients. The FDA had tentatively approved Exforge in December 2006 and has now
Shire claims that unlike some other ADHD treatments, Intuniv is not a controlled substance and does not have a known mechanism for potential abuse or dependence. “The information
The US-based pharmaceutical company says it will continue its discussions with the FDA to address outstanding questions and finalize the product labeling as soon as possible. Pfizer says
The UK Department of Health says it agrees “in principle”, but would need to look into the cost of such a program. However, the Scottish Executive plans to
Janssen Pharmaceutica Products and Alza were sued by the family of 28-year-old Adam Hendelson following his death on December 17, 2003. Both companies are subsidiaries of Johnson &
“This latest distribution agreement with AXA Diagnostics marks Rosetta Genomics’ entry into Europe, and we are excited to have AXA as our first partner in this region,” noted
The stronger formulation is efficacious enough to treat moderate to moderately-severe acne while still providing a favorable side effect profile, Galderma said. Differin Gel, 0.3% will be available
Under the terms of the agreement, Shire has the exclusive right to commercialize Juvista worldwide, with the exception of EU member states. On the FDA’s acceptance of the
Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer. The companies plan to file a supplemental new drug application with the